Corrigendum to “Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials” [Lung Cancer 120 (June) (2018) 137–141](S016950021830309X)(10.1016/j.lungcan.2018.03.020)

Hossein Maymani, Kenneth Hess, Roman Groisberg, David S. Hong, Aung Naing, Sarina Piha-Paul, Filip Janku, Siqing Fu, Apostolia M. Tsimberidou, Shubham Pant, Daniel Karp, Shuang Liu, Ming Sun, John Heymach, George Simon, Funda Meric-Bernstam, Vivek Subbiah

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret the Cancer Prevention Research Institute of Texas Grant RP110584 was incorrectly noted; it should be RP150535. This work was supported in part by Cancer Prevention Research Institute of Texas Grant RP110584 and National Center for Advancing Translational Sciences Grant UL1 TR000371 (Center for Clinical and Translational Sciences). The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)158
Number of pages1
JournalLung Cancer
Volume136
DOIs
StatePublished - Oct 2019

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

MD Anderson CCSG core facilities

  • Biostatistics Resource Group
  • Precision Oncology Decision Support

Fingerprint

Dive into the research topics of 'Corrigendum to “Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials” [Lung Cancer 120 (June) (2018) 137–141](S016950021830309X)(10.1016/j.lungcan.2018.03.020)'. Together they form a unique fingerprint.

Cite this